



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Empaveli (pegcetacoplan) Page: 1 of 2

Effective Date: 1/12/2025 Last Review Date: 11/22/2024

Applies to: Illinois New Jersey Maryland KY PRMD
 Florida Kids Pennsylvania Kids Virginia

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Empaveli under the patient's prescription drug benefit.

Description:

FDA-Approved Indication

Empaveli is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).

All other indications are considered experimental/investigational and not medically necessary

Applicable Drug List:

Empaveli

Policy/Guideline:

Documentation

Submission of the following information is necessary to initiate the prior authorization review:

Initial requests: Flow cytometry used to show results of glycosylphosphatidylinositol anchored proteins (GPI-APs) deficiency.

Continuation requests: Chart notes or medical record documentation supporting positive clinical response.

Criteria for Initial Approval:

Paroxysmal Nocturnal Hemoglobinuria

Authorization of 6 months may be granted for treatment of paroxysmal nocturnal hemoglobinuria (PNH) when ALL the following criteria are met:

- The diagnosis of PNH was confirmed by detecting a deficiency of glycosylphosphatidylinositol-anchored proteins (GPI-APs) (e.g., at least 5% PNH cells, at least 51% of GPI-AP deficient poly-morphonuclear cells).
- Flow cytometry is used to demonstrate GPI-APs deficiency.
- Member has and exhibits clinical manifestations of disease (e.g., LDH > 1.5 ULN, thrombosis, renal dysfunction, pulmonary hypertension, dysphagia).
- The requested medication will not be used in combination with another complement inhibitor (e.g., Fabhalta, Piasky, Soliris, Ultomiris) for the treatment of PNH [for Soliris (eculizumab) and Ultomiris (ravulizumab) transition to Empaveli is allowed].

Criteria for Continuation of Therapy



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Empaveli (pegcetacoplan) Page: 2 of 2

Effective Date: 1/12/2025 Last Review Date: 11/22/2024

Applies to: Illinois New Jersey Maryland KY PRMD
 Florida Kids Pennsylvania Kids Virginia

Paroxysmal Nocturnal Hemoglobinuria

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization when ALL the following criteria are met:

- There is no evidence of unacceptable toxicity or disease progression while on the current regimen.
- The member demonstrates a positive response to therapy (e.g., improvement in hemoglobin levels, normalization of lactate dehydrogenase [LDH] levels).
- The requested medication will not be used in combination with another complement inhibitor (e.g., Fabhalta, Piasky, Soliris, Ultomiris) for the treatment of PNH

Approval Duration and Quantity Restrictions:

Initial Approval: 6 months

Renewal Approval: 12 months

Quantity Level Limit: Reference Formulary for drug specific quantity level limits

References:

1. Empaveli [package insert]. Waltham, MA: Apellis Pharmaceuticals, Inc.; February 2024.
2. Parker CJ. Management of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitory therapy. *Hematology*. 2011; 21-29.
3. Borowitz MJ, Craig F, DiGiuseppe JA, et al. Guidelines for the Diagnosis and Monitoring of Paroxysmal Nocturnal Hemoglobinuria and Related Disorders by Flow Cytometry. *Cytometry B Clin Cytom*. 2010; 78: 211-230.
4. Preis M, Lowrey CH. Laboratory tests for paroxysmal nocturnal hemoglobinuria (PNH). *Am J Hematol*. 2014;89(3):339-341.
5. Parker CJ. Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. *Hematology Am Soc Hematol Educ Program*. 2016;2016(1):208-216.
6. Dezern AE, Borowitz MJ. ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 1 - clinical utility. *Cytometry B Clin Cytom*. 2018 Jan;94(1):16-22.